Literature DB >> 27383043

Both cancerous miR-21 and stromal miR-21 in urothelial carcinoma are related to tumour progression.

Rena Ohno1, Hiroshi Uozaki1, Yoshinao Kikuchi1, Arisa Kumagai1, Tatsuya Aso1, Masato Watanabe1, Shiori Watabe1, Satoru Muto2, Raizo Yamaguchi2.   

Abstract

AIMS: Urothelial carcinoma (UC) is a globally common cancer. miR-21 appears to be important in the tumorigenesis of almost all types of human cancer. However, its precise localization and significance in UC have yet to be clarified. The aim of this study was to examine miR-21 expression in UC and reveal its clinicopathological importance. METHODS AND
RESULTS: Tissue arrays of 232 UCs were examined for miR-21 by the use of in-situ hybridization. One hundred and forty-eight transurethral resection specimens and 84 surgically resected specimens were used. After miR-21 positivity had been evaluated separately in tumour cells and the tumour stroma, it was compared with clinicopathological factors and overall survival. miR-21 was strongly expressed in tumour cells in 9% of cases and in the tumour stroma in 6% of cases. Stromal miR-21 positivity was lower than that of cancerous miR-21. Both miR-21s were correlated with each other and related to tumour stage, locus, and histological grade. In addition, strong positivity of miR-21 in cancer and the stroma was significantly related to poorer prognosis among surgically resected cases. In a Cox proportional hazard model, cancerous miR-21 was the only independent prognostic factor except for tumour stage.
CONCLUSIONS: miR-21 in both cancer and stromal cells is closely related to tumour progression in UC. miR-21 may be a prognostic marker for cancer progression.
© 2016 John Wiley & Sons Ltd.

Entities:  

Keywords:  in-situ hybridization; miR-21; progression; survival; tumour stroma; urothelial carcinoma

Mesh:

Substances:

Year:  2016        PMID: 27383043     DOI: 10.1111/his.13032

Source DB:  PubMed          Journal:  Histopathology        ISSN: 0309-0167            Impact factor:   5.087


  6 in total

Review 1.  microRNA-based diagnostic and therapeutic applications in cancer medicine.

Authors:  Lorenzo F Sempere; Asfar S Azmi; Anna Moore
Journal:  Wiley Interdiscip Rev RNA       Date:  2021-05-17       Impact factor: 9.957

2.  Long noncoding RNA neuroblastoma-associated transcript 1 gene inhibits malignant cellular phenotypes of bladder cancer through miR-21/SOCS6 axis.

Authors:  Zhongyuan Liu; Dalong Xie; Hui Zhang
Journal:  Cell Death Dis       Date:  2018-10-11       Impact factor: 8.469

3.  Bladder cancer cell‑secreted exosomal miR‑21 activates the PI3K/AKT pathway in macrophages to promote cancer progression.

Authors:  Fan Lin; Hu-Bin Yin; Xin-Yuan Li; Gong-Min Zhu; Wei-Yang He; Xin Gou
Journal:  Int J Oncol       Date:  2019-12-03       Impact factor: 5.650

Review 4.  miRNA in Molecular Diagnostics.

Authors:  Maja Matulić; Paula Gršković; Andreja Petrović; Valerija Begić; Suzana Harabajsa; Petra Korać
Journal:  Bioengineering (Basel)       Date:  2022-09-09

5.  Integrative Analysis of miRNA and mRNA Expression Profiles in Calcium Oxalate Nephrolithiasis Rat Model.

Authors:  Chuangxin Lan; Dong Chen; Xiongfa Liang; Jian Huang; Tao Zeng; Xiaolu Duan; Kang Chen; Yongchang Lai; Dong Yang; Shujue Li; Chonghe Jiang; Wenqi Wu
Journal:  Biomed Res Int       Date:  2017-12-17       Impact factor: 3.411

6.  Clinicopathological significance of microRNA-21 in extracellular vesicles of pleural lavage fluid of lung adenocarcinoma and its functions inducing the mesothelial to mesenchymal transition.

Authors:  Shiori Watabe; Yoshinao Kikuchi; Shigeki Morita; Daisuke Komura; Satoe Numakura; Arisa Kumagai-Togashi; Masato Watanabe; Noriyuki Matsutani; Masafumi Kawamura; Masanori Yasuda; Hiroshi Uozaki
Journal:  Cancer Med       Date:  2020-02-24       Impact factor: 4.452

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.